Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;51(5):579-85.

Antinociceptive activities of lidocaine and the nav1.8 blocker a803467 in diabetic rats

Tufan Mert  1 , Yasemin Gunes
Affiliations

Antinociceptive activities of lidocaine and the nav1.8 blocker a803467 in diabetic rats

Tufan Mert et al. J Am Assoc Lab Anim Sci. 2012.

Abstract

The streptozocin-induced diabetic rat is a model of chronic pain that shows signs of hyperalgesia and allodynia and may replicate signs in diabetic humans. Here we investigated the antinociceptive effects of A803467, a highly selective blocker of Nav1.8 channels, in diabetic rats with painful neuropathy. We systemically (intraperitoneal) or locally (intraplantar) administered A803467 (or lidocaine, a nonselective sodium channel blocker, as a control) to diabetic rats with hyperalgesia and allodynia and then measured thermal latencies and mechanical thresholds. With intraperitoneal administration, A803467 led to 6-fold greater reduction of hyperalgesia and 2-fold greater reduction of allodynia than did lidocaine. Whereas the antihyperalgesic effects of lidocaine and A803467 were similar after intraplantar administration, A803467 (1 mg) was at least 2 times more effective as an antiallodynic than was lidocaine (0.5 mg). These results suggest that compared with lidocaine, systemic or local blockade of Nav1.8 channels by A803467 may more effectively relieve hyperalgesia and allodynia in diabetic neuropathy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
General metabolic indicators of saline-treated (nondiabetic) and STZ-treated rats. (A) Blood glucose levels were elevated after treatment with STZ compared with those in nondiabetic rats. (B) STZ induction caused significant decreases in body weight. Each point represents the mean value of 7 rats, and the vertical bars indicate 1 SD. *, Significant (P < 0.05; repeated-measures ANOVA and the posthoc Dunn test) differences between diabetic and nondiabetic groups.
Figure 2.
Figure 2.
Paw withdrawal latency after thermal stimulus. Antihyperalgesic effects of intraperitoneal administration of A803467 and lidocaine to (A) diabetic and (B) nondiabetic rats. (C) Time course of thermal hyperalgesia after STZ treatment. Each point represents the mean value of 7 rats, and the vertical bars indicate 1 SD. D, time of drug injection; arrow, pretreatment value; *, significant (P < 0.05; Kruskal–Wallis repeated-measures ANOVA with Dunn multiple-comparison tests) difference from values of DMSO only and saline groups at each time point; #, significant (P < 0.05; Kruskal–Wallis repeated-measures ANOVA with Dunn multiple-comparison tests) difference from values after 10 mg/kg A803467 and 10 mg/kg lidocaine at each time point.
Figure 3.
Figure 3.
Changes in mechanical threshold to mechanical stimulus. Antiallodynic efficacies of intraperitoneal administration of A803467 and lidocaine to (A) diabetic and (B) nondiabetic rats. (C) Time course of mechanical allodynia after STZ treatment. Each point represents the mean value of 7 rats, and the vertical bars indicate 1 SD. D, time of drug injection; arrow, pretreatment value; *, significant (P < 0.05; Kruskal–Wallis repeated-measures ANOVA with Dunn multiple-comparison tests) difference from values of DMSO only and saline groups at each time point; #, significant (P < 0.05; Kruskal–Wallis repeated-measures ANOVA with Dunn multiple-comparison tests) difference from values after 10 mg/kg A803467 and 10 mg/kg lidocaine at each time point.
Figure 4.
Figure 4.
Effects of intraplantar A803467 and lidocaine on thermal hyperalgesia in diabetic (A) and nondiabetic rats (B). Each point represents the mean value of 7 rats, and the vertical bars indicate the SD. D, time of drug injection; arrow, pretreatment value; *, significant (P < 0.05; Kruskal–Wallis repeated-measures ANOVA with Dunn multiple-comparison tests) difference from values of DMSO only and saline groups at each time point.
Figure 5.
Figure 5.
Antiallodynic effects of intraplantar A803467 and lidocaine in (A) diabetic and (B) nondiabetic rats. Each point represents the mean value of 7 rats, and the vertical bars indicate the SD; D, time of drug injection; arrow, pretreatment value; *, significant (P < 0.05; Kruskal–Wallis repeated-measures ANOVA with Dunn multiple-comparison tests) difference from values of DMSO only and saline groups at each time point; #, significant (P < 0.05; Kruskal–Wallis repeated-measures ANOVA with Dunn multiple-comparison tests) difference from values after 1 mg/kg A803467 and 1 mg/kg lidocaine at each time point.
See this image and copyright information in PMC

References

    1. Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J, Smith A, Kerr BJ, McMahon SB, Boyce S, Hill R, Stanfa LC, Dickenson AH, Wood JN. 1999. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 2:541–548 - PubMed
    1. Amaya F, Decosterd I, Samad TA, Plumpton C, Tate S, Mannion RJ, Costigan M, Woolf CJ. 2000. Diversity of expression of the sensory-neuron-specific TTX-resistant voltage-gated sodium-ion channels SNS and SNS2. Mol Cell Neurosci 15:331–342 - PubMed
    1. Andriambeloson E, Baillet C, Vitte PA, Garotta G, Dreano M, Callizot N. 2006. Interleukin-6 attenuates the development of experimental diabetes-related neuropathy. Neuropathology 26:32–42 - PubMed
    1. Bean BP. 2007. The action potential in mammalian central neurons. Nat Rev Neurosci 8:451–465 - PubMed
    1. Berkley KJ. 1997. Sex differences in pain. Behav Brain Sci 20:371–380 - PubMed

Publication types